Pipeline
Advancing AN-113 toward the clinic
Our lead program applies Annulus's centrally-selective muscarinic platform to schizophrenia.
Discovery
Preclinical / IND-Enabling
Phase 1
Phase 2
Phase 3
AN-113
M1/M4-preferring muscarinic agonist · Schizophrenia
Preclinical
AN-153
M1/M4-preferring muscarinic agonist · Unspecified psychiatric and neurodegenerative disease
Discovery
AN-136
M1-preferring muscarinic agonist · Unspecified cognitive conditions
Discovery
Additional CNS indications are under exploration as part of our broader muscarinic platform. As programs progress, we'll expand this page with additional pipeline detail.
AN-113, AN-153, and AN-136 are investigational compounds. None has been approved by the FDA or any other regulatory authority. Statements on this page describe our research approach and are not claims of safety or efficacy.